Literature DB >> 7199253

Serological investigation and clinical significance of high-titer, low-avidity (HTLA) antibodies.

M K Moulds.   

Abstract

High-titer, low-avidity (HTLA) antibodies are frequently described as "reactive weakly by the antiglobulin test." These antibodies include: anti-Chido (Cha) and anti-Rodgers (Rga), and anti-Cost-Stirling (Csa) and anti-York (Yka), anti-Knops (Kna) and anti-McCoy (McCa), and anti-John Milton Hagen (JMH), the majority of which are directed at high-incidence red cell antigens. The classic HTLA antibodies are thought to be incapable of fixing complement or causing in vitro hemolysis. Present data indicate that these antibodies do not cause either increased red cell destruction when incompatible blood is transfused or hemolytic disease of the newborn. Special serological techniques can be used to differentiate the antibodies within the HTLA classification from antibodies not of an HTLA nature.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7199253

Source DB:  PubMed          Journal:  Am J Med Technol        ISSN: 0002-9335


  5 in total

1.  CR1 Knops blood group alleles are not associated with severe malaria in the Gambia.

Authors:  P A Zimmerman; J Fitness; J M Moulds; D T McNamara; L J Kasehagen; J Alexandra Rowe; A V S Hill
Journal:  Genes Immun       Date:  2003-07       Impact factor: 2.676

2.  Prevalence and clinical significance of low-avidity HPA-1a antibodies in women exposed to HPA-1a during pregnancy.

Authors:  Julie A Peterson; Adam Kanack; Dhirendra Nayak; Daniel W Bougie; Janice G McFarland; Brian R Curtis; Richard H Aster
Journal:  Transfusion       Date:  2012-09-25       Impact factor: 3.157

3.  The C3b/C4b receptor is recognized by the Knops, McCoy, Swain-langley, and York blood group antisera.

Authors:  J M Moulds; M W Nickells; J J Moulds; M C Brown; J P Atkinson
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

4.  Identification of the Kna/Knb polymorphism and a method for Knops genotyping.

Authors:  J M Moulds; B J Thomas; O Doumbo; D A Diallo; K E Lyke; C V Plowe; J A Rowe; D J Birmingham
Journal:  Transfusion       Date:  2004-02       Impact factor: 3.157

Review 5.  Complement Receptor 1: disease associations and therapeutic implications.

Authors:  Rohan Khera; Nibhriti Das
Journal:  Mol Immunol       Date:  2008-11-11       Impact factor: 4.407

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.